# DESCRIPTION

## FIELD OF THE INVENTION

- define invention scope

## BACKGROUND

- introduce PSMA
- motivate PSMA targeting
- describe CD3
- motivate bispecific antibodies

## BRIEF SUMMARY OF THE INVENTION

- introduce anti-PSMA antibodies
- describe bispecific antibodies
- list exemplary anti-PSMA antibodies
- provide HCVR and LCVR sequences
- define antibodies with HCVR sequences
- define antibodies with LCVR sequences
- define antibodies with HCVR/LCVR pairs
- provide HCDR1 sequences
- define antibodies with HCDR1 sequences
- provide HCDR2 sequences
- define antibodies with HCDR2 sequences
- provide HCDR3 sequences
- define antibodies with HCDR3 sequences
- provide LCDR1 sequences
- define antibodies with LCDR1 sequences
- provide LCDR2 sequences
- define antibodies with LCDR2 sequences
- provide LCDR3 sequences
- define antibodies with LCDR3 sequences
- provide nucleic acid molecules encoding antibodies
- introduce invention
- provide nucleic acid molecules
- provide recombinant expression vectors
- provide host cells
- provide anti-PSMA antibodies
- provide pharmaceutical composition
- provide therapeutic methods
- provide use of anti-PSMA antibody
- provide monospecific anti-PSMA antibodies
- provide therapeutic methods for stimulating T cell activation
- provide isolated antibody or antigen-binding fragment
- provide antibody or antigen-binding fragment that competes for binding
- provide antibody or antigen-binding fragment that binds to same epitope
- provide isolated antibody or antigen-binding fragment
- provide bispecific antigen-binding molecules
- provide anti-PSMA/anti-CD3 bispecific molecules
- provide first antigen-binding domain that specifically binds CD3
- provide second antigen-binding domain that specifically binds PSMA
- provide anti-CD3/anti-PSMA bispecific molecules
- provide first antigen-binding domain that specifically binds CD3
- provide second antigen-binding domain that specifically binds PSMA
- provide anti-CD3/anti-PSMA bispecific molecules
- provide first antigen-binding domain that specifically binds CD3
- provide second antigen-binding domain that specifically binds PSMA
- provide anti-CD3/anti-PSMA bispecific molecules
- provide first antigen-binding domain that specifically binds CD3
- provide second antigen-binding domain that specifically binds PSMA
- provide anti-CD3/anti-PSMA bispecific molecules
- provide first antigen-binding domain that specifically binds CD3
- provide second antigen-binding domain that specifically binds PSMA
- introduce anti-CD3/anti-PSMA bispecific molecules
- define HCVR and LCVR sequences
- define HCVR/LCVR amino acid sequence pairs
- define HCDR3 and LCDR3 domains
- define HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 domains
- provide non-limiting, exemplary anti-CD3/anti-PSMA bispecific antigen-binding molecules
- define bispecific antigen-binding molecule with heavy and light chain CDRs
- define bispecific antigen-binding molecule with three heavy chain CDRs and three light chain CDRs
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecule with second antigen-binding domain that specifically binds human PSMA
- define bispecific antigen-binding molecules
- describe anti-CD3/anti-PSMA bispecific antigen-binding molecules
- specify antigen-binding domains
- provide examples of bispecific antigen-binding molecules
- describe binding affinity
- specify EC50 values
- describe T cell-mediated tumor cell killing
- specify KD values
- describe antibody production
- provide examples of reference antigen-binding proteins
- describe competition for binding
- specify SEQ ID NOs
- describe pharmaceutical compositions
- provide methods for treating cancer
- specify types of cancer
- describe nucleic acid molecules
- provide recombinant expression vectors
- describe host cells
- provide methods of producing antibodies
- describe anti-CD3/anti-PSMA bispecific antigen-binding molecules with modified glycosylation patterns
- provide pharmaceutical compositions with modified glycosylation patterns
- describe combinations with second therapeutic agents
- provide therapeutic methods for targeting tumor cells
- describe use in manufacturing medicaments
- provide other embodiments
- conclude description of invention

## DETAILED DESCRIPTION

- define terms and scope of invention
- introduce terminology and conventions used in patent application

### Definitions

- define CD3 and its subunits
- define human CD3-epsilon and CD3-delta
- define antibody that binds CD3
- define cell surface-expressed CD3
- define PSMA
- define antibody that binds PSMA
- define antigen-binding molecule
- define antibody
- describe structure of antibody
- define variable and constant regions
- define complementarity determining regions (CDRs)
- define framework regions (FRs)
- define antigen-binding fragment
- list examples of antigen-binding fragments
- define monospecific and multispecific antibodies
- define bispecific antibody
- describe CDC and ADCC
- define human antibody
- define recombinant human antibody
- describe hinge heterogeneity
- define isolated antibody
- describe one-arm antibody
- define germline mutations
- describe conservative substitutions
- define epitope
- define conformational and linear epitopes
- define substantial identity
- define substantial similarity
- describe conservative amino acid substitutions
- list examples of conservative substitution groups
- describe PAM250 log-likelihood matrix
- define moderately conservative replacement
- describe sequence similarity analysis software
- describe GCG software
- describe FASTA algorithm
- describe BLAST algorithm
- define antibody-dependent cell-mediated cytotoxicity (ADCC)
- define complement-dependent cytotoxicity (CDC)
- describe importance of constant region in antibody function
- describe human IgG isotypes
- describe hinge region mutations
- describe production of recombinant antibodies
- describe isolation of antibodies
- describe testing of antibodies
- describe mutations in framework and CDR regions
- describe germline mutations in framework and CDR regions
- describe conservative substitutions in framework and CDR regions
- describe epitope binding by antibodies

### Germline Mutations

- define germline mutations
- describe antibodies with germline mutations
- introduce concept of conservative amino acid substitutions
- provide examples of conservative substitutions
- define moderately conservative replacements
- introduce concept of substantial identity
- describe method for determining sequence identity
- introduce FASTA algorithm
- introduce BLAST algorithm
- describe testing of antigen-binding domains
- discuss benefits of germline mutations
- introduce concept of avidity-driven tumor therapies
- describe antibodies with combinations of germline mutations
- discuss testing of antibodies for desired properties
- summarize scope of present invention

### Binding Properties of the Antibodies

- define binding in context of antibody-antigen interaction
- describe binding affinity
- introduce concept of KD value
- describe cell-based binding strategies
- introduce concept of non-detectable binding
- define KD value in relation to binding affinity
- introduce concept of binding ratio
- define kd, ka, and KA values
- define EC50 value and its relation to binding

### Bispecific Antigen-Binding Molecules

- define bispecific antigen-binding molecules
- describe monospecific and multispecific antibodies
- introduce anti-PSMA monospecific antibodies
- introduce anti-PSMA/anti-CD3 bispecific antibodies
- describe linking or co-expressing antibodies with functional molecules
- define anti-CD3 antibody and anti-PSMA antibody
- describe CD3-binding arm and PSMA-binding arm
- introduce CD3-binding arm inducing human T cell activation
- introduce CD3-binding arm inducing tumor-associated antigen-expressing cell killing
- describe PSMA-binding arm
- introduce bispecific antigen-binding molecules binding CD3 and PSMA
- define PSMA
- describe bispecific antigen-binding molecules with weak CD3 binding affinity
- define antigen-binding molecule
- define bispecific antigen-binding molecule
- describe bispecific antibody with first and second antigen-binding domains
- introduce multimerizing domain
- describe bispecific antigen-binding molecules with two multimerizing domains
- introduce Fc fragment as multimerizing domain
- describe other multimerizing domains
- introduce bispecific antibody formats and technologies
- describe modified Fc domains with enhanced or diminished FcRn binding
- introduce specific Fc modifications
- describe bispecific antigen-binding molecules with different Ig CH3 domains
- introduce chimeric Fc domains
- describe specific chimeric Fc domains
- introduce antibody heavy chain with specific amino acid sequences

### Sequence Variants

- introduce sequence variants
- define germline mutations
- describe framework and CDR regions
- motivate conservative amino acid substitutions
- define conservative amino acid substitutions
- provide examples of conservative substitutions
- introduce antigen-binding molecules with germline mutations
- describe testing for desired properties
- introduce antigen-binding molecules with conservative substitutions
- define substantial identity
- describe measuring sequence similarity
- introduce pH-dependent binding characteristics
- define acidic and neutral pH
- describe KD ratio
- motivate obtaining antibodies with pH-dependent binding
- describe modifying antigen-binding domains
- introduce histidine residue substitution
- describe screening for pH-dependent binding
- summarize pH-dependent binding characteristics

### Antibodies Comprising Fc Variants

- introduce Fc variants
- describe mutations enhancing FcRn binding
- provide examples of Fc modifications
- summarize Fc variant antibodies

### Biological Characteristics of the Antibodies and Bispecific Antigen-Binding Molecules

- define antibodies and antigen-binding fragments
- describe binding affinity to human PSMA
- specify KD values for binding to PSMA
- describe dissociative half-life of antibodies and antigen-binding fragments
- specify t½ values for binding to PSMA
- introduce bispecific antigen-binding molecules
- describe binding to human CD3 and PSMA
- specify EC50 values for binding to CD3 and PSMA
- describe binding to human T-cell lines and PSMA-expressing cells
- specify EC50 values for binding to T cells and PSMA-expressing cells
- describe anti-CD3/anti-PSMA bispecific antigen-binding molecules
- specify EC50 values for binding to CD3 and PSMA
- describe binding to CD3-expressing human T-cells and PSMA-expressing cells
- specify EC50 values for binding to CD3-expressing T cells and PSMA-expressing cells
- describe characteristics of anti-CD3/anti-PSMA bispecific antigen-binding molecules
- specify inhibiting tumor growth in immunocompromised mice
- specify inhibiting tumor growth in immunocompetent mice
- specify suppressing tumor growth of established tumors
- specify reducing tumor growth of established tumors
- describe antibodies and antigen-binding fragments binding to human CD3
- specify KD values for binding to CD3
- describe dissociative half-life of antibodies and antigen-binding fragments binding to CD3
- specify t½ values for binding to CD3
- describe antibodies and antigen-binding fragments binding to monkey CD3
- specify KD values for binding to monkey CD3
- describe dissociative half-life of antibodies and antigen-binding fragments binding to monkey CD3
- specify t½ values for binding to monkey CD3
- describe antibodies and antigen-binding fragments inducing T cell activation
- specify EC50 values for inducing T cell activation
- describe antibodies and antigen-binding fragments inducing T cell-mediated killing
- specify EC50 values for inducing T cell-mediated killing
- describe antibodies and antigen-binding fragments binding to CD3 with weak or no detectable affinity
- specify characteristics of anti-CD3/anti-PSMA bispecific antigen-binding molecules
- describe inducing PBMC proliferation in vitro
- describe activating T-cells via inducing IFN-gamma release and CD25 up-regulation
- describe inducing T-cell mediated cytotoxicity on anti-PSMA-resistant cell lines
- describe depleting tumor antigen-expressing cells in a subject
- specify characteristics of anti-CD3/anti-PSMA bispecific antigen-binding molecules in vivo

### Epitope Mapping and Related Technologies

- define epitope
- describe epitope structure
- introduce techniques for epitope mapping
- describe cross-blocking assay
- describe alanine scanning mutational analysis
- describe peptide blots analysis
- describe peptide cleavage analysis
- describe epitope excision
- describe epitope extraction
- describe chemical modification of antigens
- describe hydrogen/deuterium exchange method
- describe X-ray crystallography
- introduce anti-PSMA antibodies
- describe bispecific antigen-binding molecules
- describe determining epitope binding
- describe determining epitope competition
- describe epitope binding and competition analysis

### Preparation of Antigen-Binding Domains and Construction of Bispecific Molecules

- prepare antigen-binding domains
- construct bispecific antigen-binding molecules
- discuss bispecific antibody formats
- derive multispecific antigen-binding molecules from chimeric, humanized or fully human antibodies
- make antibodies using VELOCIMUNE technology
- characterize and select antibodies for desirable characteristics
- replace mouse constant regions with human constant regions
- use genetically engineered animals to make human bispecific antigen-binding molecules
- produce fully human bispecific antigen-binding molecules using engineered mice
- discuss engineered mice and their use in producing bispecific antigen-binding molecules
- introduce bioequivalents
- define bioequivalents
- discuss pharmaceutical equivalents or pharmaceutical alternatives
- discuss bioequivalence measures
- demonstrate bioequivalence by in vivo and in vitro methods
- construct bioequivalent variants of bispecific antigen-binding molecules
- make substitutions of residues or sequences
- delete terminal or internal residues or sequences
- modify glycosylation characteristics
- introduce species selectivity and species cross-reactivity
- provide antigen-binding molecules that bind to human CD3 and/or PSMA
- provide antigen-binding molecules that bind to human CD3 and/or PSMA and one or more non-human species
- introduce immunoconjugates
- conjugate antigen-binding molecules to therapeutic moieties
- introduce therapeutic formulation and administration
- formulate pharmaceutical compositions with suitable carriers and excipients
- discuss delivery systems and administration routes
- describe injectable preparations
- prepare injectable preparations
- describe dosage forms
- specify amount of antibody per dosage form
- introduce therapeutic uses
- describe therapeutic composition
- specify pharmaceutically acceptable carrier or diluent
- define subject in need thereof
- describe diseases or disorders to be treated
- specify mechanism of action
- describe cells to be inhibited or killed
- specify cancers to be treated
- describe analytic/diagnostic methods
- define residual cancer
- describe treatment of residual cancer
- specify timing of treatment
- introduce combination therapies
- describe additional therapeutic agents
- specify pharmaceutical compositions
- describe therapeutic regimens
- introduce administration regimens
- describe multiple doses
- specify sequential administration
- define initial, secondary, and tertiary doses
- describe frequency of administration
- specify loading and maintenance doses
- describe diagnostic uses
- specify detection and measurement of PSMA
- describe diagnostic assays
- specify labels and reporter molecules
- describe 89Zr-labeled antibody
- specify PET imaging
- describe ELISA, RIA, and FACS assays
- specify sample types
- describe baseline levels of PSMA

## EXAMPLES

- provide examples of methods and compositions of the invention

### Example 1: Generation of Anti-PSMA Antibodies

- immunize genetically modified mouse with human PSMA antigen
- harvest splenocytes and fuse with mouse myeloma cells or B-cell sort
- characterize and select antibodies for desirable characteristics

### Example 2: Heavy and Light Chain Variable Region Amino Acid and Nucleic Acid Sequences of Anti-PSMA Antibodies

- set forth amino acid sequence identifiers of heavy and light chain variable regions and CDRs

### Example 3: Surface Plasmon Resonance Derived Binding Affinities and Kinetic Constants of Human Monoclonal Anti-PSMA Antibodies

- assess binding affinities and kinetic constants of anti-PSMA antibodies to human PSMA
- determine kinetic association and dissociation rate constants
- calculate binding dissociation equilibrium constants and dissociative half-lives

### Example 4: Generation of Bispecific Antibodies that Bind Prostate-Specific Membrane Antigen (PSMA) and CD3

- construct bispecific antibodies with anti-PSMA and anti-CD3 antigen binding domains
- describe component parts of antigen-binding domains of bispecific antibodies
- set forth amino acid sequence identifiers of heavy chain variable regions and CDRs
- set forth nucleotide sequence identifiers of heavy chain variable regions and CDRs
- describe light chain variable regions and CDRs common to both arms
- set forth amino acid sequence identifiers of light chain variable regions and CDRs
- set forth nucleotide sequence identifiers of light chain variable regions and CDRs

### Example 5: Binding Affinities of Exemplified Bispecific Antibodies as Measured by FACS Analysis

- determine binding affinities of bispecific antibodies to human PSMA-expressing cell lines
- determine binding affinities of bispecific antibodies to human CD3-expressing cell lines
- determine EC50 for cell binding titration
- analyze binding specificity to human PSMA-expressing cell lines
- analyze binding specificity to human CD3-expressing cell lines

### Example 6: Binding Affinities of Exemplified Antibodies as Measured by a Surface Plasmon Resonance Binding Assay

- determine binding affinities and kinetic constants of bispecific antibodies to soluble CD3 protein
- determine kinetic association and dissociation rate constants
- calculate binding dissociation equilibrium constants and dissociative half-lives

### Example 7: T Cell Activation and Tumor-Specific Cytotoxicity Exhibited by Bispecific Antibodies of the Invention as Measured In Vitro

- monitor specific killing of PSMA-expressing target cells
- assess T cell activation by bispecific antibodies
- determine EC50 for T cell activation and cytotoxicity
- analyze specificity of killing by bispecific antibodies
- analyze correlation between T cell activation and cytotoxicity

### Example 8: Anti-PSMA/Anti-CD3 Bispecific Antibodies Display Potent Anti-Tumor Efficacy In Vivo

- introduce bispecific antibodies
- describe xenograft models
- detail human tumor xenograft studies
- outline treatment protocol
- present results of tumor growth inhibition
- describe efficacy in established human tumor xenograft model
- detail treatment protocol for established tumors
- present results of established tumor study
- describe efficacy in immune-competent tumor model
- detail treatment protocol for immune-competent model
- present results of immune-competent model study
- describe efficacy on established tumors in immune-competent model
- detail treatment protocol for established tumors in immune-competent model
- present results of established tumor study in immune-competent model
- summarize anti-tumor efficacy of bispecific antibodies

### Example 9: Generation of Anti-CD3 Antibodies

- generate anti-CD3 antibodies
- immunize engineered mouse with CD3 or DNA encoding CD3
- monitor antibody immune response by CD3-specific immunoassay
- harvest splenocytes and fuse with mouse myeloma cells
- screen and select hybridoma cell lines for CD3-specific antibodies
- obtain chimeric anti-CD3 antibodies with human variable domains and mouse constant domains
- isolate fully human anti-CD3 antibodies from antigen-positive B cells
- describe biological properties of anti-CD3 antibodies
- set forth amino acid sequence identifiers of heavy and light chain variable regions
- set forth nucleic acid sequence identifiers of heavy and light chain variable regions
- describe nomenclature for anti-CD3 antibodies
- describe control constructs used in experiments
- generate pool of anti-CD3 antibodies from genetically modified mouse
- test antibodies for affinity to human and cynomolgus monkey CD3 antigen
- identify antibodies with high affinity to CD3
- engineer antibodies with germline frameworks
- replace amino acid residues in stepwise manner
- investigate binding affinities and kinetics of anti-CD3 antibodies
- describe surface plasmon resonance derived binding affinities and kinetic constants
- determine kinetic association and dissociation rate constants
- calculate binding dissociation equilibrium constants and dissociative half-lives
- test anti-CD3 antibodies for binding to human T-cells
- test anti-CD3 antibodies for inducing T-cell proliferation
- test anti-CD3 antibodies for binding to monkey T-cells
- test anti-CD3 antibodies for inducing monkey T-cell proliferation
- study ability of anti-CD3 antibodies to redirect T-cell mediated killing
- use calcein based U937 killing assay
- calculate EO50 values for CD3 antibodies
- describe scope of the invention

